

Amendment to the Claims

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1. (Currently amended) A method of treating Parkinson's disease in a human in need of such treatment comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of ~~a dopaminergic agent pergolide, a monoamine oxidase agent~~ an antiparkinson therapeutic amount of selegiline, and an anti-inflammatory effective amount of ~~a selective COX-2 inhibitor rofecoxib (VIOXX®)~~.

2. to 11. (Cancelled)

12. (Currently amended) A method of relieving the symptoms of Parkinson's disease, which method comprises administration to a patient in need of such treatment of ~~an amount of a selective COX-2 inhibitor, a dopaminergic agent and a monoamine oxidase agent~~ an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline, and an anti-inflammatory effective amount of rofecoxib (VIOXX®), such that together they provide effective relief.

13. (Currently amended) A method of treating Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a ~~selective COX-2 inhibitor, a dopaminergic agent and a monoamine oxidase agent~~ an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline, and an anti-inflammatory effective amount of rofecoxib (VIOXX®), such that together the agents provide greater relief than that obtained by administration of the antiparkinson agent alone.

14. (Currently amended) A method for ameliorating the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a ~~therapeutically effective amount of a selective COX-2 inhibitor, a dopaminergic agent and a monoamine oxidase agent~~ an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline, and an anti-inflammatory effective amount of rofecoxib (VIOXX®), such that together they provide effective amelioration.

15. (Currently amended) A method for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of ~~a therapeutically effective amount of a selective COX-2 inhibitor, a dopaminergic agent and a monoamine oxidase agent~~ an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline, and an anti-inflammatory effective amount of rofecoxib (VIOXX®), such that together they are effective in slowing the progress of the disease.

16. - 21. (Cancelled)